Common Contracts
8 similar Agreement and Plan of Merger contracts by Aeglea BioTherapeutics, Inc., Aprea Therapeutics, Inc., Baudax Bio, Inc., others
AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...Agreement and Plan of Merger • December 22nd, 2023 • Spyre Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...Agreement and Plan of Merger • November 15th, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER by and amongAgreement and Plan of Merger • November 13th, 2023 • Selecta Biosciences Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of November 13, 2023, by and among SELECTA BIOSCIENCES, INC., a Delaware corporation (“Parent”), SAKURA MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SAKURA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER among: BAUDAX BIO, INC., BOUNCE MERGER SUB I, INC., BOUNCE MERGER SUB II, LLC, and TERAIMMUNE, INC. Dated as of June 29, 2023Agreement and Plan of Merger • July 5th, 2023 • Baudax Bio, Inc. • Services-misc health & allied services, nec • Delaware
This AGREEMENT AND PLAN OF MERGER is made and entered into as of June 29, 2023, by and among Baudax Bio, Inc., a Pennsylvania corporation (“Parent”), Bounce Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), Bounce Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and TeraImmune, Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER by and among: AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation; ASPEN MERGER SUB I, INC., a Delaware corporation; SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company; and SPYRE THERAPEUTICS, INC., a...Agreement and Plan of Merger • June 23rd, 2023 • Aeglea BioTherapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of June 22, 2023, by and among AEGLEA BIOTHERAPEUTICS, INC., a Delaware corporation (“Parent”), ASPEN MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), SEQUOIA MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and SPYRE THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER among: IDERA PHARMACEUTICALS, INC., a Delaware corporation; BELL MERGER SUB I, INC., a Delaware corporation; BELL MERGER SUB II, LLC, a Delaware limited liability company; and ACERAGEN, INC., a Delaware corporation Dated...Agreement and Plan of Merger • September 30th, 2022 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER is made and entered into as of September 28, 2022, by and among IDERA PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), BELL MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), BELL MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and, together with First Merger Sub, “Merger Subs”), and ACERAGEN, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER among: APREA THERAPEUTICS, INC., a Delaware corporation; ATR MERGER SUB I INC., a Delaware corporation; ATR MERGER SUB II LLC, a Delaware limited liability company; and ATRIN PHARMACEUTICALS INC., a Delaware corporation...Agreement and Plan of Merger • May 17th, 2022 • Aprea Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of May 16, 2022, by and among Aprea Therapeutics, Inc., a Delaware corporation (“Parent”), ATR Merger Sub I Inc., a Delaware corporation and wholly owned Subsidiary of Parent (“First Merger Sub”), ATR Merger Sub II LLC, a Delaware limited liability company and wholly owned Subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and Atrin Pharmaceuticals Inc., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT AND PLAN OF MERGER among: MIRAGEN THERAPEUTICS, INC., a Delaware corporation; OCULUS MERGER SUB I, INC., a Delaware corporation; OCULUS MERGER SUB II, LLC, a Delaware limited liability company; and VIRIDIAN THERAPEUTICS, INC., a Delaware...Agreement and Plan of Merger • October 28th, 2020 • Miragen Therapeutics, Inc. • Services-medical laboratories • Delaware
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of October 27, 2020, by and among MIRAGEN THERAPEUTICS, INC., a Delaware corporation (“Parent”), OCULUS MERGER SUB I, INC., a Delaware corporation and wholly owned subsidiary of Parent (“First Merger Sub”), OCULUS MERGER SUB II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Second Merger Sub” and together with First Merger Sub, “Merger Subs”), and VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
